The C18orf32 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 liver adenocarcinoma cell line. This product offers a heterogeneous pool of cells carrying targeted disruptions in the C18orf32 gene, enabling functional investigation of this uncharacterized protein-coding locus. The polyclonal format circumvents potential clonal artifacts and provides a representative loss-of-function model for assessing gene function in a cancer cell context.
SK-HEP-1 is an immortalized adherent cell line originally isolated from the ascitic fluid of a patient with liver adenocarcinoma. Widely used as a hepatocellular carcinoma (HCC) model, these malignant epithelial cells retain key features of hepatic tumorigenesis and are amenable to a range of in vitro assays. The SK-HEP-1 background is well-characterized for studies of cancer cell proliferation, migration, invasion, and drug response, making it a relevant system for exploring novel genes implicated in liver cancer biology.
C18orf32 is a predicted protein-coding gene of unknown function, with no validated interacting partners, upstream regulators, or downstream targets currently reported. The absence of characterized pathway affiliations underscores the need for exploratory research using knockout models. CRISPR/Cas9-mediated disruption of C18orf32 in SK-HEP-1 cells provides a clean genetic background to uncover its potential role in cellular processes such as proliferation, apoptosis, or migration, which are often dysregulated in cancer.
The combination of an uncharacterized gene and a well-established hepatocellular carcinoma model offers a unique opportunity to discover novel molecular drivers of liver cancer. By ablating C18orf32 expression in a polyclonal population, researchers can observe functional consequences without the confounding effects of clonal selection. This system is particularly valuable for generating unbiased hypotheses regarding gene function and for identifying phenotypic changes that may contribute to tumorigenesis or drug sensitivity.
Typical applications include functional genomics screens, transcriptomic analysis via RNA-seq, protein-level confirmation by Western blotting or RT-qPCR, and phenotypic assays such as MTT-based proliferation, apoptosis (e.g., Annexin V staining), wound-healing migration, and chemosensitivity testing. The knockout cells enable both gain- and loss-of-function comparisons when paired with overexpression or rescue constructs. For further information on technical specifications, validation data, and ordering, please contact Ascent Research.
